Navigation Links
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
Date:6/13/2010

Previous data shows that a reduction in CHOP chemotherapy dose intensity below 90%(ii) may decrease survival in patients with aggressive NHL.

"These data confirm the significant impact febrile neutropenia can have on chemotherapy delivery in NHL, possibly reducing the favourable outcome of the treatment. There is a need for early prophylaxis with G-CSFs in those patients at risk," said Dr Ruth Pettengell, presenting author of the study and Senior Lecturer in Haematology and Honorary Consultant in Oncology at St George's Hospital Medical School, University of London.

Unplanned hospitalisations were also greater in patients who experienced FN (79% versus 18% in R-CHOP-21; 78% versus 21% in R-CHOP-14).

Based on these data from everyday clinical practice, the authors conclude physicians should implement guidelines on G-CSF use and G-CSF primary prophylaxis should be considered for NHL patients receiving R-CHOP-21 chemotherapy, who are assessed as having an overall FN risk of 20% or higher, and for all patients receiving R-CHOP-14.

Use of G-CSF primary phrophylaxis to prevent FN differed between the two groups; less than half of R-CHOP-21 patients (36%) were given G-CSF primary prophylaxis, compared to 84% of the R-CHOP-14 group and incidence of FN was 19% and 20% respectively.

About the Study

The aim of the IMPACT NHL study was to assess the impact of febrile neutropenia (FN) on non-Hodgkin lymphoma (NHL) patients receiving CHOP chemotherapy in combination with rituximab(R) every two (14 days) or three (21 days) weeks (current standard of care).

The study was supported by Amgen and included a total of 1,829 patients over the age of 18 with NHL receiving either R-CHOP-14 or R-
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
3. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
4. Vivakor Confirms Record Date of Stock Dividend
5. New study confirms exotic electric properties of graphene
6. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
7. Analysis confirms that nano-related research has strong multidisciplinary roots
8. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
11. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2
... Shows No Thrombosis, Low MACE Rates ... Thirty Patients, ABBOTT PARK, Ill., March 13 ... first clinical trial of a,fully bioabsorbable drug eluting stent ... thrombosis, no clinically driven target,lesion revascularizations (retreatment of a ...
... BERKELEY, Calif., March 13 Nile Therapeutics,Inc. (OTC ... and,full year financial results for 2007. Participants may ... the investor relations section of,Nile,s website at ... company,s website until the next quarterly conference call., ...
... Unigene,Laboratories, Inc. (OTCBB: UGNE) announced that it ... release titled "Stonegate Report About Unigene,Laboratories Inc.", ... Company,s,policies and procedures, Unigene does not endorse, ... by analysts and unrelated third,parties. Any opinions, ...
Cached Biology Technology:The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3Unigene Restates Policy on Analyst Reports 2
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
(Date:7/28/2014)... by the U.S. Food and Drug Administration (FDA) for ... bacterial pathogens inside human cells, including those that cause ... published in mBio , the online open-access journal ... way of identifying non-antibiotic drugs that could one day ... drugs on the list inhibit the growth of at ...
(Date:7/28/2014)... by the University of Arizona has sequenced the complete ... enhance scientists, and agriculturalists, understanding of the growing patterns ... of new rice varieties that are better able to ... hunger challenges. , The paper, "The genome sequence of ... independent domestication," was published online in Nature Genetics ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4
... Hospital have discovered a new genetic disease that can lead ... bile is missing, the liver cells are exposed to the ... a transformation of liver cells into connective tissue with a ... the cases of liver cirrhosis of unknown origin and open ...
... Meyskens, Jr., M.D., one of the "fathers" of ... to receive the seventh annual American Association for ... in Cancer Prevention Research. The award is ... to the field of cancer prevention research in ...
... Jewish Health have identified a simple gene-based blood test ... response to therapy than current tests. The test, a ... and help clear a backlog of promising medications now ... the results of a small "proof-of-principal" trial in the ...
Cached Biology News:Toxic bile damages the liver 2Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
Biology Products: